COVID-19疫苗相關白斑症：一項在三級轉診中心的橫斷面研究及系統綜述

摘 要：

隨著嚴重急性呼吸綜合徵冠狀病毒2型（SARS-CoV-2）在全球範圍內繼續感染患者，疫苗接種仍然是對抗這場持久大流行的主要方法之一。然而，越來越多的報告指出，2019冠狀病毒病（COVID-19）疫苗可能引發自身免疫反應，這一現象無論疫苗設計如何均有所觀察。這種情況在白斑症患者中尤其顯著，越來越多的病例報告顯示接種COVID-19疫苗後出現新發或惡化的白斑症。 本研究中，作者呈現了迄今為止最大規模的COVID-19疫苗相關白斑症病例系列，並進行了系統文獻綜述。本研究的目的是幫助臨床醫生在面對白斑症患者時，對未來疫苗接種的臨床評估提供參考。我們希望通過這項研究，為醫生提供有價值的數據和建議，以更好地管理和預防與COVID-19疫苗相關的白斑症病例。

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to infect patients globally, vaccination remains one of the primary methods to combat this prolonged pandemic. However, there are growing reports of coronavirus disease 2019 (COVID-19) vaccines possibly triggering autoimmunity, irrespective of the vaccine's design. This phenomenon has been observed in patients with vitiligo, with a rising number of cases reporting new-onset or worsening vitiligo following COVID-19 vaccinations. In this study, the authors present the most extensive case series of COVID-19 vaccine–associated vitiligo to date, along with a systematic review of the literature. The aim is to assist physicians in the clinical evaluation of patients with vitiligo with regard to future vaccinations.